Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts

Circulation

Volumn 93, Issue 1, 1996, Pages 135-142

  McCormack, James G ^c   Barr, Rick L ^a   Wolff, Andrew A ^b   Lopaschuk, Gary D ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b ROCHE BIOSCIENCE   (United States)

^c HERIOT WATT UNIVERSITY   (United Kingdom)

Author keywords

fatty acids; glucose; glycolysis; ischemia; reperfusion

Indexed keywords

RANOLAZINE;

ANIMAL TISSUE; ARTICLE; DRUG EFFECT; FATTY ACID OXIDATION; GLYCOLYSIS; HEART HEMODYNAMICS; HEART MUSCLE ISCHEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

EID: 0030032681     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.1.135     Document Type: Article

References (35)

1. +] and pH in a canine model of transient myocardial ischaemia. Biochem Soc Trans. 1987;15:1057-1058.
2. Allely MC, Alps BJ. Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion. Br J Pharmacol. 1990;99:5-6.
3. 1-adrenoceptors in the rat left ventricle by ischaemia and acyl carnitines: protection by ranolazine. J Cardiovasc Pharmacol. 1993;21:869-873.
4. Ferrandon P, Pascal J-C, Armstrong JM. Protective effects of the novel anti-ischemic agent ranolazine (RS-43285) in the reperfused rat heart. Br J Pharmacol. 1988;93:247.
5. Clarke B, Spedding M, Patmore L, McCormack JG. Protective effects of ranolazine in guinea pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase. Br J Pharmacol. 1993;109:748-750.
6. Gralinski MR, Black SC, Kilgore KS, Chou AY, McCormack JG, Lucchesi BR. Cardioprotective effects of ranolazine (RS-43285) in the isolated perfused rabbit heart. Cardiovasc Res. 1994;28: 1231-1237.
7. Cocco G, Rousseau MF, Bouvy T, Cheron P, Williams G, Detry JM, Pouleur H. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol. 1992;20:131-138.
8. Bouvy T, Rousseau MF, Cocco G, Cheron P, William GJ, Detry JMR. Improvement in exercise tolerance and left ventricular filling dynamics in patients with angina pectoris with the novel metabolic modulator, ranolazine. Acta Cardiol. 1993;48:98-99.
9. Rousseau MF, Visser FG, Bax JJ, Dubrey S, Cocco G, Pouleur H, Harris SR, Wolff AA. Ranolazine: anti-anginal therapy with a novel mechanism: controlled comparison versus atenolol. Eur Heart J. 1994;15:95. Abstract.
10. Smith WB, Chrysant S, Garland WT, Parker S, Walpole HT, Mokatrin A, Gennevois D, Pepine CJ. A multicenter controlled trial of a novel metabolic active compound (ranolazine) in chronic stable angina patients. J Am Coll Cardiol. In press.
11. Randle PJ. Fuel selection in animals. Biochem Soc Trans. 1986;14: 799-806.
12. McVeigh JJ, Lopaschuk GD. Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic hearts. Am J Physiol. 1990;259:H1079-H1085.
13. Burkhoff D, Permanetter B, Yaffe S. Influence of metabolic substrate on rat heart function and metabolism at different coronary flows. Am J Physiol. 1991;261:H741-H750.
14. Lopaschuk GD, Wambolt RB, Barr RL. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J Pharmacol Exp Ther. 1993;264:135-144.
15. Broderick TL, Quinney HA, Barker CC, Lopaschuk GD. Beneficial effect of carnitine on mechanical recovery of rat hearts reperfused after a transient period of global ischemia is accompanied by a stimulation of glucose oxidation. Circulation. 1993;87:972-981.
16. Boddeke E, Hugtenburger J, Jap W, Heynis J, Van Zweiten P. New anti-ischaemic drugs: cytoprotective action with no primary haemodynamic effects. Trends Pharmacol Sci. 1989;10:397-400.
17. Pepine CJ. A new therapeutic approach to myocardial ischemia. J Myocardial Ischemia. 1993;5:9-10.
18. Chierchia SL, Fragasso G. Metabolic management of ischaemic heart disease. Eur Heart J. 1993;14(suppl G):2-5.
19. Collins-Nakai RL, Barr R, Humen D, Lopaschuk GD. Ranolazine stimulates glucose oxidation in isolated working rat hearts. Can J Cardiol. 1993;9(suppl E):33. Abstract.
20. Gamble J, Collins-Nakai RL, Barr R, Humen D, Lopaschuk GD. Ranolazine stimulates glucose oxidation in isolated working rat hearts. Can J Physiol Pharmacol. 1994;72(suppl 1):96. Abstract.
21. Saddik M, Lopaschuk GD. Myocardial triglyceride turnover and contribution to energy substrate utilisation in isolated working rat hearts. J Biol Chem. 1991;266:8162-8170.
22. Finegan BA, Lopaschuk GD, Coulson CS, Clanachan AS. Adenosine alters glucose use during ischemia and reperfusion in isolated rat hearts. Circulation. 1993;87:900-908.
23. Oliver MF, Kuren VA, Greenwood TW. Relation between serum free fatty acids and arrhythmia and death after myocardial infarction. Lancet. 1969;1:710-714.
24. Allison SP, Chamberlain MJ, Hinton P. Intravenous glucose tolerance, insulin, glucose and free fatty acid levels after myocardial infarction. Br Med J. 1969;4:776-778.
25. Svensson S, Svedjeholm R, Ekroth R, Milocco I, Nilsson F, Sabel KG, William-Olsson G. Trauma metabolism in the heart: uptake of substrates and the effects of insulin early after cardiac operations. J Thorac Cardiovasc Surg. 1990;99:1063-1073.
26. Clarke B, Wyatt KM, McCormack JG. Ranolazine increases active pyruvate dehydrogenase (PDH) in perfused normoxic rat hearts. J Mol Cell Cardiol. 1994;26:CLXXIV.
27. McCormack JG, Halestrap AP, Denton RM. Role of calcium ions in regulation of mammalian intramitochondrial metabolism. Physiol Rev. 1990;70:391-425.
28. Hutter JF, Piper HM, Spieckermann PG. Effects of fatty acid oxidation on efficiency of energy production in rat heart. Am J Physiol. 1985;249:H723-H728.
29. Davies NJ, Schulz R, Olley PM, Strynadka KD, Panas DL, Lopaschuk GD. Lysoplasmenylethanolamine accumulation in ischemic/ reperfused isolated fatty acid-perfused hearts. Circ Res. 1992;70: 1161-1168.
30. DaTorre SD, Creer MH, Pogwizd SM, Corr PB. Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart. J Mol Cell Cardiol. 1991;23(suppl I):11-22.
31. Lopaschuk GD, Belke DD, Gamble J, Itoi T, Schönekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochim Biophys Acta. 1994;1213:263-276.
32. Selby PL, Sherratt HSA. Substituted 2-oxiranecarboxylic acids: a new group of candidate hypoglycaemic drugs. Trends Pharmacol Sci. 1989;10:495-500.
33. Paulson DJ, Noonan JJ, Ward KM, Sherratt HSA, Shug A. Effects of POCA on metabolism and function in the ischemic rat heart. Basic Res Cardiol. 1986;81:180-187.
34. Koundakjian PP, Turnbull DM, Bone AJ, Rogers MP, Younan SI, Sherratt HSA. Metabolic changes in fed rats caused by chronic administration of ethyl-2[5(4-chlorophenyl) pentyl]oxirane-2-carboxylate, a new hypoglycaemic compound. Biochem Pharmacol. 1984;33:465-473.
35. Lopaschuk GD, Spafford M. Response of isolated working hearts to fatty acids and carnitine palmitoyltransferase I inhibition during reduction of coronary flow in acutely and chronically diabetic rats. Circ Res. 1989;65:378-387.